A new analysis of the AZA-001 phase III clinical trial shows that Vidaza significantly improves response rates for higher-risk MDS patients. Continued treatment with Vidaza leads to improved responses in nearly half of patients, offering hope for those who initially have a weak response.
Patients with acute myeloid leukemia who received VIDAZA had significantly increased overall survival compared to those treated with conventional care regimens. Approximately half of the AML patients treated with VIDAZA survived at least two years, compared to just 16% of those receiving conventional chemotherapy.
A subanalysis of the AZA-001 phase III trial reveals Vidaza extends overall survival and reduces death risk in elderly higher-risk MDS patients. The treatment also improves one-year survival rates in all response categories.